Comparison of the efficacy and tolerability of adapalene gel 0.1% versus tretinoin gel 0.05% in patients with mild to moderate acne vulgaris

Comparison of the efficacy and tolerability of adapalene gel 0.1% versus tretinoin gel 0.05% in patients with mild to moderate acne vulgaris: a double blinded randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201403109014N31

Enrollment

Registered

2014-03-25

Start date

1991-12-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. Acne vulgaris

Interventions

Treatment - Drugs

Rubbing adapalene gel 0.1% on the area of facial acne lesion once a day for 12 weeks.

Rubbing tretinoin gel 0.05% on the area of facial acne lesion once a day for 12 weeks

Intervention 1: Rubbing adapalene gel 0.1% on the area of facial acne lesion once a day for 12 weeks. Intervention 2: Rubbing tretinoin gel 0.05% on the area of facial acne lesion once a day for 12 we

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Any patient with mild to moderate acne vulgaris without limitation of age and gender. Exclusion criteria: (a) Pregnancy or breast feeding; (b) using medication that have interaction with the drug under study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluation of the improvement of acne lesions. Timepoint: at zero time and then at 4th and 12th weeks after treatment. Method of measurement: based on the Global Acne Grading System with comparison of the photos taken from the location of the lesions.	—

Secondary

Measure	Time frame
Local dry skin. Timepoint: at 4th and 12th weeks after treatment. Method of measurement: through physical examination.;Local erythema. Timepoint: at 4th and 12th weeks after treatment. Method of measurement: through clinical examination.;Local skin irritation. Timepoint: at 4th and 12th weeks after treatment. Method of measurement: through taking history of the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Bita Sharafi

Farshchian Hospital

bita_sharafi@yahoo.com+98 81 1838 1086

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026